project administration, M.G
Others may not qualify, prefer not to take injections, or simply want to start with lifestyle changes first
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Cannot redeclare control with same name "grid_2_qv_cta_shadow_hover_box_shadow_type"
The portion of ALCAR that does survive intact is uniquely capable of crossing the blood-brain barrier, a feat that LCT cannot achieve
.png)
